Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women

Clinical Drug Investigation

Volumn 30, Issue 5, 2010, Pages 325-336

  Kelly, Sue ^a   Davies, Emyr ^b   Fearns, Simon ^c   McKinnon, Carol ^d   Carter, Rick ^e   Gerlinger, Christoph ^f   Smithers, Andrew ^g  

^a Connaught Clinical Consulting ^*  (Australia)

^b Waterfront Medical Centre   (United Kingdom)

^c Castlemilk Health Centre ^*

^d Castlemilk Health Centre   (United Kingdom)

^e Bayer Schering Pharma AG   (United Kingdom)

^f BAYER PHARMA AG   (Germany)

^g AP Clinical Services Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYL ESTRADIOL, LEVONORGESTREL DRUG COMBINATION; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BODY WATER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MENSTRUAL CYCLE; MULTICENTER STUDY; NONPARAMETRIC TEST; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; ANDROSTENES; BODY WATER; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; MENSTRUAL CYCLE; QUALITY OF LIFE; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 77953260002     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11535450-000000000-00000     Document Type: Article

References (25)

1. Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001; 41: 875-86
2. Gold MA, Johnson LM. Intrauterine devices and adolescents. Curr Opin Obstet Gynecol 2008 Oct; 20 (5): 464-9
3. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62 (1): 29-38
4. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000 Jun; 5 (2): 124-34
5. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000 Feb; 61 (2): 105-11
6. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000 Mar; 5 (1): 25-34
7. Borenstein J, Yu HT, Wade S, et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003 Feb; 48 (2): 79-85
8. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001 Jul-Aug; 10 (6): 561-9
9. Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone: effect on premenstrual symptoms. J Reprod Med 2002 Jan; 47 (1): 14-22
10. Boschitsch E, Skarabis H, Wuttke W, et al. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 2000 Dec; 5 Suppl. 3: 34-40
11. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004 Aug; 74 (2): 123-30
12. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002 Apr; 69 (4 Suppl.): 2-15
13. Wharton C, Blackburn R. Moving to lower doses - oral contraceptives: population reports 1988 [online]. Available from URL: http://findarticles.com/p/ articles/mi-m0856/is-n3-v16/ai-7918131 [Accessed 2009 Feb 23]
14. Moos RH. The development of a menstrual distress questionnaire. Psychosom Med 1968 Nov-Dec; 30 (6): 853-67
15. Gerlinger C, Endrikat J, Kallischnigg G, et al. Evaluation of menstrual bleeding patterns: a new proposal for a universal guideline based on the analysis of more than 4500 bleeding diaries. Eur J Contracept Reprod Health Care 2007 Sep; 12 (3): 203-11
16. Gerlinger C, Endrikat J, van der Meulen EA, et al. Recommendation for confidence interval and sample size calculation for the Pearl Index. Eur J Contracept Reprod Health Care 2003 Jun; 8 (2): 87-92
17. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000 Feb; 95 (2): 261-6
18. Sulak PJ, Kuehl TJ, Ortiz M, et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002 Jun; 186 (6): 1142-9
19. Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995 Jun 12; 761: 311-35
20. Darney PD. The androgenicity of progestins. Am J Med 1995 Jan 16; 98 (1A): 104S-10S
21. Oranratanaphan S, Taneepanichskul S. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido. J Med Assoc Thai 2006 Oct; 89 Suppl. 4: S17-22
22. Endrikat J, JaquesMA,MayerhoferM, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995 Oct; 52 (4): 229-35
23. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997 Mar; 55 (3): 131-7
24. Endrikat J, Dusterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999 Nov; 60 (5): 269-74
25. Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 1999 Nov; 181 (5 Pt 2): 39-44